CLINICAL PHARMACOLOGICAL APPROACH TO DRUGS USED IN THE TREATMENT OF THROMBOEMBOLIC SYNDROME IN THE ELDERLY
Main Article Content
Abstract
Anemia and venous thromboembolic complications are conditions that are not specific to any one nosology. Today, erythropoiesis-stimulating drugs are widely used to correct anemia. However, an increase in hemoglobin/hematocrit is not unambiguously positive, since it can potentially increase the tendency to thrombosis in the venous bed. This tendency is expressed differently in different diseases and conditions. Opinions on erythropoiesis-stimulating drugs as real risk factors for the development of venous thromboembolic complications also differ.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Human Biology Knowledge Base. http://humbio.ru/humbio/har/00633104.htm
Hawkins D. Pharmacotherapy 2014; 24: 173–83.
Schulman S. In: Lugassy et al. Martin Dunitz, London 2020; p. 37–51.
Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythro- poiesis-stimulating agents. Semin Thromb Hemost 2010; 36 (5): 537–43.
Bokemeyer C, Aapro MS, Courdi A et al. European Organization for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer: 2006 update. Eur J Cancer 2017; 43 (2): 258–70.